[Clinical and laboratory efficacy of triovit in patients with grade I renal impairment].
Results are submitted of the investigation designed to study efficacy of the use of the antioxidant drug "Triovit" in patients with chronic glomerulonephritis and chronic pyelonephritis in grade I chronic renal impairment (CRI). It has been ascertained that the use of the drug triovit results in activation of the antioxidant system which is noted to be depressed in CRI patients. The above drug was found to lower a toxic effect of lipid peroxidation at the level of membrane structures and body as a whole, with rate of CRI progression tending to slow down.
Zhelekhovs'kyi
O A
OA
D000328:Adult; D000975:Antioxidants / Q000627:therapeutic use*; D005260:Female; D005921:Glomerulonephritis / Q000150:complications / Q000188:drug therapy; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy* / Q000209:etiology; D015227:Lipid Peroxidation / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D011704:Pyelonephritis / Q000150:complications / Q000188:drug therapy
D000975:Antioxidants
Kliniko-laboratorna efektyvnist' "Triovitu" u khvorykh z khronichnoiu nyrkovoiu nedostatnistiu I stupenia.